Transform the industry with technology to create healthier lives


Driven by technology innovation,
the Health segment focuses on the three major areas of pharmaceutical,
devices and diagnosis, and healthcare services and products.

  • 5.0 RMB billion

    Fosun Pharma's subsidiary, Fosun Health Capital, won the bid to manage the first batch of "20+8" industry funds in Shenzhen, exclusively managing a RMB5.0 billion biopharmaceutical industry fund
  • HANSIZHUANG (serplulimab injection)

    Independently developed by Fosun is the world’s first monoclonal antibody drug targeting PD-1 approved for the first-line treatment of small cell lung cancer.Approved for four indications in the Chinese mainland
    The first China-produced anti-PD-1 monoclonal antibody approved for marketing in Southeast Asia
  • HANQUYOU (trastuzumab injection)

    The first China-developed monoclonal antibody biosimilar approved in China, Europe, and U.S.
    Launched in more than 40 countries and regions
  • Yi Kai Da (ejilunsai injection)

    The first CAR-T cell therapy product approved for marketing in China
    Second-line indication approved in Chinese Mainland
    Benefited more than 600 lymphoma patients in China since its launch
  • Artesun® & Argesun® (artesunate for injection)

    Treated more than 68 million severe malaria patients
    The second generation, Argesun® became the world’s first artesunate injectable presented with a single solvent system that received WHO Prequalification (WHO PQ)
  • Domestically-produced da Vinci Xi Surgical System

    Approved for launch by NMPA in June 2023
    The first domestically-produced da Vinci Xi Surgical System was officially put into use, achieving the localization and commercialization of the system

  • Focused ultrasound

    Collaborated with Insightec to establish a JV Fosun-Insightec and commenced the commercialization, clinical application and R&D of focused brain ultrasound platform in the Chinese market

  • New markets

    Sisram launched two products, Soprano Titanium and Alma Opus to new markets
    Breas completed domestic manufacturing conversion and upgrading of various ventilators
  • Ion Bronchial Navigation Operation Control System (Ion System)

    Approved by NMPA
  • 6,548 beds 1

    Approved beds in the controlled medical institutions under Fosun Health
    1Bed count sourced from controlled subsidiaries, excluding Jianjia Healthcare, as of 31 December 2023
  • Pharmaceutical Manufacturing
  • Devices & Diagnosis
  • Healthcare Services And Products